Cutaneous Pseudolymphoma Clinical Presentation
- Author: Christine J Ko, MD; Chief Editor: William D James, MD more...
Patients with B-cell pattern pseudolymphoma present with a nodule or a group of discrete nodules, usually with minimal associated symptoms. Occasionally, patients present with pruritus or pain. Patients with a T-cell pattern of cutaneous pseudolymphoma usually present with broader patches, which are often asymptomatic.
The onset of drug-induced pseudolymphoma is insidious. Most patients present with a single slowly enlarging papular, nodular, or plaquelike lesion several weeks following the initiation of implicated medications. However, several patients have demonstrated drug-induced pseudolymphoma after more than 5 years of therapy.
Examination of patients with a B-cell pattern of pseudolymphoma usually reveals a single nodule, from one to several centimeters in diameter. Although the lesions may be soft, they are more often firm. Typically, the lesions are red to purple in color, but they may show no coloration. Approximately three quarters of cases of cutaneous pseudolymphoma are localized. The remaining cases usually show grouped papules in a single defined region. More disseminated cases are rare. The most common site of involvement in cutaneous pseudolymphoma is the face (70%), followed by the chest and the upper extremities. Cutaneous pseudolymphoma lesions are infrequent below the waist.
Sites of predilection for borrelial pseudolymphoma include the earlobe, the nipple, the areola, the nose, and the scrotum (sites of low skin temperature).
Patients with T-cell pattern pseudolymphoma typically present with broad, erythematous patches and/or plaques. Pseudolymphomatous actinic reticuloid affects sun-exposed areas. Lymphomatoid contact dermatitis demonstrates lesions in areas where the inciting agent has come in contact with the skin.
Erythematous patches, similar to mycosis fungoides (MF), may be seen, but, in contrast to MF, they may be more localized and not restricted to sun-protected sites. Frequently, a small number of erythematous indurated papules, plaques, or nodules are seen. Rarely, a solitary tumor may appear.
Brodell RT, Santa Cruz DJ. Cutaneous pseudolymphomas. Dermatol Clin. 1985 Oct. 3(4):719-34. [Medline].
Choi TS, Doh KS, Kim SH, Jang MS, Suh KS, Kim ST. Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome. Br J Dermatol. 2003 Apr. 148(4):730-6. [Medline].
Bergman R. Pseudolymphoma and cutaneous lymphoma: facts and controversies. Clin Dermatol. 2010 Sep-Oct. 28(5):568-74. [Medline].
Albrecht J, Fine LA, Piette W. Drug-associated lymphoma and pseudolymphoma: recognition and management. Dermatol Clin. 2007 Apr. 25(2):233-44, vii. [Medline].
Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996 Dec. 15(4):250-7. [Medline].
Callot V, Roujeau JC, Bagot M, Wechsler J, Chosidow O, Souteyrand P, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol. 1996 Nov. 132(11):1315-21. [Medline].
Maubec E, Pinquier L, Viguier M, et al. Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol. 2005 Apr. 52(4):623-9. [Medline].
Magro CM, Crowson AN, Kovatich AJ, Burns F. Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells. Hum Pathol. 2003 Feb. 34(2):119-29. [Medline].
Ploysangam T, Breneman DL, Mutasim DF. Cutaneous pseudolymphomas. J Am Acad Dermatol. 1998 Jun. 38(6 Pt 1):877-95; quiz 896-7. [Medline].
Magro CM, Crowson AN. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis. Hum Pathol. 1996 Feb. 27(2):125-32. [Medline].
Cerroni L, Kerl H. Diagnostic immunohistology: cutaneous lymphomas and pseudolymphomas. Semin Cutan Med Surg. 1999 Mar. 18(1):64-70. [Medline].
Kazandjieva J, Tsankov N. Tattoos: dermatological complications. Clin Dermatol. 2007 Jul-Aug. 25(4):375-82. [Medline].
Porto DA, Comfere NI, Myers LM, Abbott JJ. Pseudolymphomatous reaction to varicella zoster virus vaccination: role of viral in situ hybridization. J Cutan Pathol. 2009 Nov 4. [Medline].
Michaels B, Michaels J, Mobini N. Prominent lymphoid infiltrate with a pseudolymphoma-like morphology: a new histological finding of injectable liquid silicone. J Cutan Pathol. 2009 Nov. 36(11):1224-6. [Medline].
Camilot D, Arnez ZM, Luzar B, Pizem J, Zgavec B, Falconieri G. Cutaneous pseudolymphoma following tattoo application: report of two new cases of a potential lymphoma mimicker. Int J Surg Pathol. 2012 Jun. 20(3):311-5. [Medline].
Altamura D, Calonje E, Liau Jl, Rogers M, Verdolini R. Diffuse cutaneous pseudolymphoma due to therapy with medicinal leeches. JAMA Dermatol. 2014 Jul. 150(7):783-4. [Medline].
Bouloc A, Delfau-Larue MH, Lenormand B, Meunier F, Wechsler J, Thomine E, et al. Polymerase chain reaction analysis of immunoglobulin gene rearrangement in cutaneous lymphoid hyperplasias. French Study Group for Cutaneous Lymphomas. Arch Dermatol. 1999 Feb. 135(2):168-72. [Medline].
Baldassano MF, Bailey EM, Ferry JA, Harris NL, Duncan LM. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features. Am J Surg Pathol. 1999 Jan. 23(1):88-96. [Medline].
Kitagawa KH, Grassi M. Zoledronic acid-induced cutaneous B-cell pseudolymphoma. J Am Acad Dermatol. 2011 Dec. 65(6):1238-40. [Medline].
Addeo R, Montella L, Baldi A, Cennamo G, Guarrasi R, Faiola V, et al. Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma. Clin Colorectal Cancer. 2007 Nov. 6(10):728-30. [Medline].
Welsh JP, Ko C, Hsu WT. Lymphomatoid drug reaction secondary to methylphenidate hydrochloride. Cutis. 2008 Jan. 81(1):61-4. [Medline].
Braun RP, French LE, Feldmann R, Chavaz P, Saurat JH. Cutaneous pseudolymphoma, lymphomatoid contact dermatitis type, as an unusual cause of symmetrical upper eyelid nodules. Br J Dermatol. 2000 Aug. 143(2):411-4. [Medline].
Goyal A, Moore JB, Gimbel D, Carter JB, Kroshinsky D, Ferry JA, et al. PD-1, S-100 and CD1a expression in pseudolymphomatous folliculitis, primary cutaneous marginal zone B-cell lymphoma (MALT lymphoma) and cutaneous lymphoid hyperplasia. J Cutan Pathol. 2015 Jan. 42 (1):6-15. [Medline].
Bachelez H. The clinical use of molecular analysis of clonality in cutaneous lymphocytic infiltrates. Arch Dermatol. 1999 Feb. 135(2):200-2. [Medline].
Burg G, Kerl H, Schmoeckel C. Differentiation between malignant B-cell lymphomas and pseudolymphomas of the skin. J Dermatol Surg Oncol. 1984 Apr. 10(4):271-5. [Medline].
El-Dars LD, Statham BN, Blackford S, Williams N. Lymphocytoma cutis treated with topical tacrolimus. Clin Exp Dermatol. 2005 May. 30(3):305-7. [Medline].
Baumgartner-Nielsen J, Lorentzen H. Imiquimod 5%: a successful treatment for pseudolymphoma. Acta Derm Venereol. 2014 Jul. 94(4):469. [Medline].
Singletary HL, Selim MA, Olsen E. Subcutaneous interferon alfa for the treatment of cutaneous pseudolymphoma. Arch Dermatol. 2012 May. 148(5):572-4. [Medline].
Tomar S, Stoll HL, Grassi MA, Cheney R. Treatment of cutaneous pseudolymphoma with interferon alfa-2b. J Am Acad Dermatol. 2009 Jan. 60(1):172-4. [Medline].
Mikasa K, Watanabe D, Kondo C, Tamada Y, Matsumoto Y. Topical 5-aminolevulinic acid-based photodynamic therapy for the treatment of a patient with cutaneous pseudolymphoma. J Am Acad Dermatol. 2005 Nov. 53(5):911-2. [Medline].
Lucinda TS, Hazel OH, Joyce LS, Hon CS. Successful Treatment of Tattoo-Induced Pseudolymphoma with Sequential Ablative Fractional Resurfacing Followed by Q-Switched Nd: YAG 532 nm Laser. J Cutan Aesthet Surg. 2013 Oct. 6(4):226-8. [Medline]. [Full Text].